News
Clinical Trials Arena on MSN11d
First subject dosed in Vantage’s Phase II trial for diabetic retinopathyVantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat ...
Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat non-proliferative diabetic retinopathy (NPDR). The multi-centre, placebo-controlled ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback